HER2 Gene Mutation Completed Phase 2 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0081068 (HER2 Gene Mutation)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03845270Her2-positive Lung Cancer Treated With Dedicated DrugTreatment